SEC Comment Letter for Edesa Biotech, Inc. (EDSA) (CIK 0001540159) (EDSA) — Mar 7, 2025
Edesa Biotech, Inc. (EDSA) (CIK 0001540159)
Date: March 7, 2025 · CIK: 0001540159 · Accession: 0000000000-25-002559
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285539
Letter
Re: Edesa Biotech, Inc. Registration Statement on Form S-3 Filed March 4, 2025 File No. 333-285539 Dear Stephen Lemieux:
March 7, 2025
Stephen Lemieux Chief Financial Officer Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, Canada L3R 5H6
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Tracy Buffer
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 7, 2025 Stephen Lemieux Chief Financial Officer Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, Canada L3R 5H6 Re: Edesa Biotech, Inc. Registration Statement on Form S-3 Filed March 4, 2025 File No. 333-285539 Dear Stephen Lemieux: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Tracy Buffer </TEXT> </DOCUMENT>